Evidence map›Paper›PMID 38678524›Full record

ArticleJournal of cancer survivorship : research and practice2024

Determining the relationship of p16

Ashley E Rosko, Mohamed I Elsaid, Jennifer Woyach, Nowshin Islam, Noah Lepola, Jazmin Urrutia, Lisa M Christian, Carolyn Presley, Alice Mims, Christin E Burd

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ashley E RoskoDivision of Hematology, The Ohio State University, Columbus, OH, USA. Ashley.Rosko@osumc.edu.
Mohamed I ElsaidDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
Jennifer WoyachDivision of Hematology, The Ohio State University, Columbus, OH, USA.
Nowshin IslamDivision of Hematology, The Ohio State University, Columbus, OH, USA.
Noah LepolaDepartments of Molecular Genetics, Cancer Biology and Genetics, The Ohio State University, Columbus, OH, USA.
Jazmin UrrutiaDepartments of Molecular Genetics, Cancer Biology and Genetics, The Ohio State University, Columbus, OH, USA.
Lisa M ChristianDepartment of Psychiatry and Behavioral Health, Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.
Carolyn PresleyDivision of Medical Oncology, The Ohio State University, Columbus, OH, USA.
Alice MimsDivision of Hematology, The Ohio State University, Columbus, OH, USA.
Christin E BurdDepartments of Molecular Genetics, Cancer Biology and Genetics, The Ohio State University, Columbus, OH, USA.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

purposeOlder adults with hematologic malignancies (HM) have unique challenges due to age and fitness. The primary aim of this pilot study was to benchmark the ability of multiple biomarkers of aging (p16, epigenetic clocks, T cell gene expression profiles, and T cell receptor excision circles (TREC) to identify frailty as measured by a clinical impairment index (I

methods70 patients newly diagnosed with HM had peripheral blood T lymphocytes (PBTL) analyzed for p16

resultsAge-adjusted p16

conclusionsOur pilot data suggest that multiple blood-based aging biomarkers have potential to identify frailty in older adults with HM. IMPLICATIONS FOR CANCER SURVIVORS: We developed the I

Indexed as

AgingCyclin-Dependent Kinase Inhibitor p16FrailtyHematologic NeoplasmsAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedPilot ProjectsBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Aging biomarkersFrailtyHematologic Malignancyp16

Identifiers

PMID38678524
PMCPMC11324703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.